<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00168337</url>
  </required_header>
  <id_info>
    <org_study_id>206207-011</org_study_id>
    <nct_id>NCT00168337</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone
      for the treatment of diabetic macular edema.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With a Best Corrected Visual Acuity (BCVA) Improvement of ≥15 Letters From Baseline in the Study Eye</measure>
    <time_frame>Baseline, Month 39/Final Visit</time_frame>
    <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Change From Baseline in BCVA in the Study Eye</measure>
    <time_frame>Baseline, 39 Months</time_frame>
    <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The average BCVA is calculated across study visits for each patient. A positive number change from baseline indicates an improvement and a negative number change from baseline indicates a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in BCVA in the Study Eye</measure>
    <time_frame>Baseline, Month 39/Final Visit</time_frame>
    <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive number change from baseline indicates an improvement and a negative number change from baseline indicates a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With a BCVA Improvement of ≥10 Letters From Baseline in the Study Eye</measure>
    <time_frame>Baseline, Month 39/Final Visit</time_frame>
    <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Retinal Thickness as Measured by Optical Coherence Tomography (OCT)</measure>
    <time_frame>Baseline, Month 39/Final Visit</time_frame>
    <description>OCT is a laser-based, noninvasive, diagnostic system that provides high-resolution, three-dimensional images of the retina from which retinal thickness can be measured. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">554</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Dexamethasone 700 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone 350 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
    <arm_group_label>Dexamethasone 700 μg</arm_group_label>
    <arm_group_label>Dexamethasone 350 μg</arm_group_label>
    <other_name>Posurdex®</other_name>
    <other_name>Ozurdex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Sham posterior segment drug delivery system-needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  18 years of age or older with diabetic macular edema;

          -  Decrease in visual acuity in at least one eye as a result of macular edema (20/50 or
             worse);

          -  Visual acuity in other eye no worse than 20/200

        Key Exclusion Criteria:

          -  Known anticipated need for ocular surgery within next 12 months;

          -  History of glaucoma or current high eye pressure requiring more than 1 medication;

          -  Uncontrolled systemic disease;

          -  Known steroid-responder;

          -  Use of systemic steroids;

          -  Use of Warfarin/Heparin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>July 10, 2014</results_first_submitted>
  <results_first_submitted_qc>July 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2014</results_first_posted>
  <disposition_first_submitted>May 30, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>May 30, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 7, 2013</disposition_first_posted>
  <last_update_submitted>July 10, 2014</last_update_submitted>
  <last_update_submitted_qc>July 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexamethasone 700 μg</title>
          <description>700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
        </group>
        <group group_id="P2">
          <title>Dexamethasone 350 μg</title>
          <description>350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
        </group>
        <group group_id="P3">
          <title>Sham</title>
          <description>Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="181"/>
                <participants group_id="P3" count="185"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="112"/>
                <participants group_id="P3" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="103"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexamethasone 700 μg</title>
          <description>700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
        </group>
        <group group_id="B2">
          <title>Dexamethasone 350 μg</title>
          <description>350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
        </group>
        <group group_id="B3">
          <title>Sham</title>
          <description>Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="188"/>
            <count group_id="B2" value="181"/>
            <count group_id="B3" value="185"/>
            <count group_id="B4" value="554"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 to 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With a Best Corrected Visual Acuity (BCVA) Improvement of ≥15 Letters From Baseline in the Study Eye</title>
        <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening.</description>
        <time_frame>Baseline, Month 39/Final Visit</time_frame>
        <population>Intent to Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone 700 μg</title>
            <description>700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone 350 μg</title>
            <description>350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
          </group>
          <group group_id="O3">
            <title>Sham</title>
            <description>Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With a Best Corrected Visual Acuity (BCVA) Improvement of ≥15 Letters From Baseline in the Study Eye</title>
          <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening.</description>
          <population>Intent to Treat: all randomized patients</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3"/>
                    <measurement group_id="O2" value="18.2"/>
                    <measurement group_id="O3" value="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Change From Baseline in BCVA in the Study Eye</title>
        <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The average BCVA is calculated across study visits for each patient. A positive number change from baseline indicates an improvement and a negative number change from baseline indicates a worsening.</description>
        <time_frame>Baseline, 39 Months</time_frame>
        <population>Intent to Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone 700 μg</title>
            <description>700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone 350 μg</title>
            <description>350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
          </group>
          <group group_id="O3">
            <title>Sham</title>
            <description>Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Change From Baseline in BCVA in the Study Eye</title>
          <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The average BCVA is calculated across study visits for each patient. A positive number change from baseline indicates an improvement and a negative number change from baseline indicates a worsening.</description>
          <population>Intent to Treat: all randomized patients</population>
          <units>Letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.9" spread="9.83"/>
                    <measurement group_id="O2" value="55.2" spread="9.69"/>
                    <measurement group_id="O3" value="57.0" spread="8.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average Change from Baseline Over 39 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="8.55"/>
                    <measurement group_id="O2" value="2.9" spread="7.67"/>
                    <measurement group_id="O3" value="2.0" spread="8.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in BCVA in the Study Eye</title>
        <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive number change from baseline indicates an improvement and a negative number change from baseline indicates a worsening.</description>
        <time_frame>Baseline, Month 39/Final Visit</time_frame>
        <population>Intent to Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone 700 μg</title>
            <description>700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone 350 μg</title>
            <description>350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
          </group>
          <group group_id="O3">
            <title>Sham</title>
            <description>Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in BCVA in the Study Eye</title>
          <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive number change from baseline indicates an improvement and a negative number change from baseline indicates a worsening.</description>
          <population>Intent to Treat: all randomized patients</population>
          <units>Letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.9" spread="9.83"/>
                    <measurement group_id="O2" value="55.2" spread="9.69"/>
                    <measurement group_id="O3" value="57.0" spread="8.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 39/Final Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="17.03"/>
                    <measurement group_id="O2" value="1.4" spread="15.17"/>
                    <measurement group_id="O3" value="-0.0" spread="15.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With a BCVA Improvement of ≥10 Letters From Baseline in the Study Eye</title>
        <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening.</description>
        <time_frame>Baseline, Month 39/Final Visit</time_frame>
        <population>Intent to Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone 700 μg</title>
            <description>700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone 350 μg</title>
            <description>350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
          </group>
          <group group_id="O3">
            <title>Sham</title>
            <description>Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With a BCVA Improvement of ≥10 Letters From Baseline in the Study Eye</title>
          <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening.</description>
          <population>Intent to Treat: all randomized patients</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6"/>
                    <measurement group_id="O2" value="29.8"/>
                    <measurement group_id="O3" value="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Retinal Thickness as Measured by Optical Coherence Tomography (OCT)</title>
        <description>OCT is a laser-based, noninvasive, diagnostic system that provides high-resolution, three-dimensional images of the retina from which retinal thickness can be measured. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
        <time_frame>Baseline, Month 39/Final Visit</time_frame>
        <population>Intent to Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone 700 μg</title>
            <description>700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone 350 μg</title>
            <description>350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
          </group>
          <group group_id="O3">
            <title>Sham</title>
            <description>Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Retinal Thickness as Measured by Optical Coherence Tomography (OCT)</title>
          <description>OCT is a laser-based, noninvasive, diagnostic system that provides high-resolution, three-dimensional images of the retina from which retinal thickness can be measured. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
          <population>Intent to Treat: all randomized patients</population>
          <units>Microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="179"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="486.0" spread="163.12"/>
                    <measurement group_id="O2" value="475.4" spread="160.70"/>
                    <measurement group_id="O3" value="453.7" spread="135.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 39/Final Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-117.9" spread="227.16"/>
                    <measurement group_id="O2" value="-131.2" spread="204.33"/>
                    <measurement group_id="O3" value="-70.4" spread="180.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>10th Percentile for Time to BCVA Improvement of ≥15 Letters From Baseline in the Study Eye</title>
        <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). Shorter durations of time to improvement are best. The 10th percentile represents the first 10% of patients to reach a BCVA improvement of ≥15 letters from baseline in the study eye.</description>
        <time_frame>Baseline, 39 Months</time_frame>
        <population>Intent to Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone 700 μg</title>
            <description>700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone 350 μg</title>
            <description>350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
          </group>
          <group group_id="O3">
            <title>Sham</title>
            <description>Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>10th Percentile for Time to BCVA Improvement of ≥15 Letters From Baseline in the Study Eye</title>
          <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). Shorter durations of time to improvement are best. The 10th percentile represents the first 10% of patients to reach a BCVA improvement of ≥15 letters from baseline in the study eye.</description>
          <population>Intent to Treat: all randomized patients</population>
          <units>Days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="24"/>
                    <measurement group_id="O2" value="49" lower_limit="33"/>
                    <measurement group_id="O3" value="186" lower_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Percentage of Patients With BCVA Improvement of ≥15 Letters From Baseline in the Study Eye at 3-month Intervals</title>
        <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening.</description>
        <time_frame>Baseline, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24, Month 27, Month 30, Month 33, Month 36, Month 39/Final Visit</time_frame>
        <population>Intent to Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone 700 μg</title>
            <description>700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone 350 μg</title>
            <description>350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
          </group>
          <group group_id="O3">
            <title>Sham</title>
            <description>Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With BCVA Improvement of ≥15 Letters From Baseline in the Study Eye at 3-month Intervals</title>
          <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening.</description>
          <population>Intent to Treat: all randomized patients</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7"/>
                    <measurement group_id="O2" value="14.4"/>
                    <measurement group_id="O3" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5"/>
                    <measurement group_id="O2" value="6.1"/>
                    <measurement group_id="O3" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="14.4"/>
                    <measurement group_id="O3" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                    <measurement group_id="O2" value="9.9"/>
                    <measurement group_id="O3" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                    <measurement group_id="O2" value="14.4"/>
                    <measurement group_id="O3" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2"/>
                    <measurement group_id="O2" value="10.5"/>
                    <measurement group_id="O3" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="9.4"/>
                    <measurement group_id="O3" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1"/>
                    <measurement group_id="O2" value="9.4"/>
                    <measurement group_id="O3" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5"/>
                    <measurement group_id="O2" value="12.2"/>
                    <measurement group_id="O3" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="12.2"/>
                    <measurement group_id="O3" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="14.4"/>
                    <measurement group_id="O3" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7"/>
                    <measurement group_id="O2" value="16.6"/>
                    <measurement group_id="O3" value="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 39/Final Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3"/>
                    <measurement group_id="O2" value="18.2"/>
                    <measurement group_id="O3" value="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The Safety Population included all treated patients and was used for adverse event (AE) and Serious Adverse Event (SAE) reporting.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dexamethasone 700 μg</title>
          <description>700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
        </group>
        <group group_id="E2">
          <title>Dexamethasone 350 μg</title>
          <description>350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.</description>
        </group>
        <group group_id="E3">
          <title>Sham</title>
          <description>Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Anaemia of Chronic Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Second Degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Ischaemic Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Mitral Valve Incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cardiac Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Coronary Artery Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Pulseless Electrical Activity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Ventricular Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo Positional</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Vitreous Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Macular Oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Macular Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cataract Subcapsular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Necrotising Retinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Open Angle Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cataract Cortical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cystoid Macular Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Diabetic Retinal Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Diabetic Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Hyalosis Asteroid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Hypomotility</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Small Intestinal Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Medical Device Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Device Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Hepatic Cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Staphylococcal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Incision Site Infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Pneumonia Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Gallbladder Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Localised Infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Meniscus Lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cartilage Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Ligament Sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Fibula Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Limb Injury</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Craniocerebral Injury</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Comminuted Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>In-Stent Coronary Artery Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Tendon Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Meniscal Degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Spinal Column Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Eagles Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Foot Deformity</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Patellofemoral Pain Syndrome</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Benign Gastric Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Bladder Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Lung Squamous Cell Carcinoma Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Lung Squamous Cell Carcinoma Stage Unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Ovarian Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Transitional Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Gastric Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Hepatic Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Chronic Lymphocytic Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Carotid Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Altered State of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Benign Intracranial Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Haemorrhage Intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cerebral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>VIIth Nerve Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cervical Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cystitis Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Diabetic Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Renal Failure Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Calculus Ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Uterine Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Panniculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Victim of Homicide</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Malignant Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Extremity Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Hypovolaemic Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Temporal Arteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Venous Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="172" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="157" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Conjunctival Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Macular Oedema</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Visual Acuity Reduced</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cataract Subcapsular</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Diabetic Retinal Oedema</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Vitreous Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Macular Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Ocular Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Retinal Exudates</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Dry Eye</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Vitreous Detachment</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Lenticular Opacities</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Retinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Diabetic Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Conjunctival Oedema</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Conjunctival Hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Eye Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Punctate Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Retinal Neovascularisation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cataract Cortical</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Retinal Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular Pressure Increased</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

